KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Emergent BioSolutions (EBS) Long-Term Debt Repayments (2017 - 2021)

Emergent BioSolutions has reported Long-Term Debt Repayments over the past 6 years, most recently at $10.6 million for Q1 2021.

For Q1 2021, Long-Term Debt Repayments changed N/A year-over-year to $10.6 million; the TTM value through Dec 2021 reached $10.6 million, changed N/A, while the annual FY2021 figure was $10.6 million, N/A changed from the prior year.
Long-Term Debt Repayments for Q1 2021 was $10.6 million at Emergent BioSolutions, down from $20.0 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $20.0 million in Q1 2017 and troughed at $10.6 million in Q1 2021.